Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: A questionnaire study from one physician’s practice

Journal of Women's Health and Gender-Based Medicine

Volumn 11, Issue 3, 2002, Pages 291-301

  Rohatgi, Nitin ^a   Blau, Robbin ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; FEMALE; HOT FLUSH; HUMAN; LIBIDO DISORDER; MEDICAL PRACTICE; MOOD DISORDER; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SIDE EFFECT; VAGINA DISCHARGE; VAGINAL DRYNESS; WEIGHT GAIN; ADULT; AFFECTIVE NEUROSIS; AGED; DISEASE SEVERITY; FREQUENCY ANALYSIS; LIBIDO; MAJOR CLINICAL STUDY; VAGINA DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HOT FLASHES; HUMANS; LIBIDO; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; QUESTIONNAIRES; RALOXIFENE; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS; VAGINAL DISCHARGE; WEIGHT GAIN;

EID: 0036245417     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460902753668484     Document Type: Article

References (15)

1. Cancer statistics, 2001
2. Tamoxifen for early breast cancer: An overview of the randomized trials
3. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer
4. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
5. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
6. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects
7. Tamoxifen in the treatment of breast cancer
8. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
9. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
10. Raloxifene reduces incident primary breast cancers: Integrated data from multi-center, double-blind, placebo-controlled randomized trials in postmenopausal women
11. The risk of premature menopause induced by chemotherapy for early breast cancer
12. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
13. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
14. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study
15. Effects of high dose raloxifene in selected patients with advanced breast carcinoma